Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Aptamer GroupFRA:P0J Quick Ratio is 1.99 as of Dec. 2025, which is at its 10-year median of 1.99. The stock has 4 warning signs investors should review. Among 1,409 Biotechnology companies, Aptamer Group ranks worse than 65.51% on this metric.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Aptamer Group's quick ratio for the quarter that ended in Dec. 2025 was 1.99.
Aptamer Group has a quick ratio of 1.99. It generally indicates good short-term financial strength.
The historical rank and industry rank for Aptamer Group's Quick Ratio or its related term are showing as below:
FRA:P0J'
s Quick Ratio Range Over the Past 10 Years
Min: 0.84 Med: 1.99 Max: 3.6
Current: 1.99
During the past 6 years, Aptamer Group's highest Quick Ratio was 3.60. The lowest was 0.84. And the median was 1.99.
FRA:P0J's Quick Ratio is ranked worse than 65.51% of 1409
companies
in the Biotechnology industry
Industry Median: 3.59
vs FRA:P0J: 1.99
Aptamer Group (FRA:P0J) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Aptamer Group Quick Ratio Related Terms
Aptamer Group Quick Ratio Historical Data
* Premium members only.
The historical data trend for Aptamer Group's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:P0J vs VRTX, REGN, RVMD: Quick Ratio Comparison
For the Biotechnology subindustry, Aptamer Group's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aptamer Group Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Aptamer Group's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Aptamer Group's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Aptamer Group's Quick Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aptamer Group (FRA:P0J) has a Quick Ratio of 1.99 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aptamer Group and its competitors. This is near median its historical median of 1.99. Over the past decade, Aptamer Group's Quick Ratio has ranged from 0.84 to 3.60. According to the industry distribution chart, Aptamer Group ranks #923 out of 1409 companies in the Biotechnology industry, placing it in the top 65.5%.
Is Aptamer Group's Quick Ratio too high?
Aptamer Group's current Quick Ratio of 1.99 is near median its 10-year median of 1.99. Over the past 10 years, this metric has ranged from a low of 0.84 to a high of 3.60. The Biotechnology industry median Quick Ratio is 3.59. Aptamer Group's value of 1.99 is 44.6% below this industry median. Based on the distribution chart, Aptamer Group ranks #923 out of 1409 companies in the Biotechnology industry, which is below the industry midpoint.
How does Aptamer Group's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Aptamer Group ranks #923 out of 1409 companies for Quick Ratio. This places Aptamer Group in the lower half of its industry. The industry median Quick Ratio is 3.59. Aptamer Group's value of 1.99 is 44.6% below this benchmark. Historically, Aptamer Group's own Quick Ratio has ranged from 0.84 to 3.60 over the past decade. While the company's 10-year median is 1.99 vs. the industry median of 3.59, Aptamer Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.59, based on 1,409 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aptamer Group's current Quick Ratio of 1.99 is 44.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Aptamer Group and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aptamer Group's current Quick Ratio is 1.99, which is near median its own 10-year median of 1.99. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aptamer Group stock overvalued right now?
Aptamer Group (FRA:P0J) has a current Quick Ratio of 1.99. The current Quick Ratio is 1.99, which is near median its 10-year median of 1.99 and 44.6% below the Biotechnology industry median of 3.59. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Aptamer Group (FRA:P0J), the current Quick Ratio is 1.99 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Aptamer Group PLC provides Optimer binders for use in research, diagnostics and therapeutics. It strives to deliver transformational solutions that meet the needs of researchers and developers across the life sciences through the use of its proprietary Optimer technology. Its businesses, Aptamer Solutions for custom Optimer development, Aptamer Diagnostics for in-house and collaborative Optimer-based diagnostic development and Aptamer Therapeutics for the development of Optimer-based therapeutics. The Group represents a single operating segment being research and experimental development of biotechnology. It operates in United Kingdom, Europe, USA and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:P0J has been successfully added to your 
